[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pharyngitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pharyngitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,83,111,132,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100524897","best-assessment-of-sore-throat-and-antibiotic-prescribing-100524897",false,"NCT06114706","Best Assessment of Sore Throat and Antibiotic Prescribing","BASTA","Inclusion Criteria:\n\n* The patient is contacting\u002Fattending PHC centre or Pharmacy presenting with a sore throat as the main complaint.\n* Male or female, aged ≥6 years.\n* Fluent in Swedish (reading, writing, conversational) (applicable to caregivers\u002Fparents\u002Fguardians in case of children).\n* Mental state such that he or she can understand and give informed consent to participation in the study by signing the Information and Consent Form.\n* Provision of signed and dated Informed Consent Form.\n\nExclusion Criteria:\n\n* The illness episode is classified as potentially complicated or potentially critically ill\n* Presence of SARS-CoV-2 virus in a patient first appearing at the PHC in a cluster where the assessment is supposed to be done by the pharmacists. The patient will not be sent to the pharmacist in case of presence of SARS-CoV-2-virus.\n* Patient request to be withdrawn from the study.","ALL","6 Years",{"count":19,"type":20},450,"ESTIMATED","INTERVENTIONAL",[23],"NA","This project aims to investigate if an organisational change of patient flow away from medical practitioners can reduce unnecessary antibiotic prescribing in patients attending with a sore throat as the main complaint.",[26],"Pharyngitis",[28,29,30,31,32],"Guideline","Sore throat","Pharmacy","Nurses","Physicians","RECRUITING","2026-03-12",{"date":36,"type":37},"2026-03-16","ACTUAL",{"date":39,"type":37},"2024-03-04",{"date":41,"type":20},"2027-06-30",{"name":43,"class":44},"Vastra Gotaland Region","OTHER_GOV",4,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100600150","perspectives-on-antibiotics-and-tracking-symptoms-in-children-100600150","NCT07093749","Perspectives on Antibiotics and Tracking Symptoms in Children","PATSy Perspectives on Antibiotics and Tracking Symptoms in Children - a Mixed Methods Feasibility Study","PATSy","Inclusion Criteria:\n\n* Between the ages of ≥ 4 years and ≤ 17 years at enrolment.\n* Diagnosed with any of the following at RCH ED: urinary tract infection (UTI), cellulitis, impetigo, pharyngitis, tonsillitis, respiratory tract infections, otitis media.\n* Prescribed oral antibiotics (either immediately or as switch from IV antibiotics after transfer to HITH) as standard of care due to having uncomplicated infection as deemed by their treating doctor.\n* Parent\u002Fguardian provides a signed and dated informed consent form.\n\nExclusion Criteria:\n\n\\- Parent\u002Fguardian does not speak English","4 Years","17 Years",{"count":57,"type":20},300,[23],"The study will assess families' perspectives and decision-making regarding the duration of oral antibiotic courses prescribed to children (4-17 years) who present with uncomplicated bacterial infections at the Royal Children's Hospital (RCH) Emergency Department (ED). The study will involve (i) children discharged from ED on oral antibiotics and (ii) children transferred to Hospital-in-the-Home (HITH) on IV antibiotics who then switch to oral antibiotics. In addition, the study will assess how feasible and acceptable it is to track children's symptoms via the Garmin Smartwatch and the WeGuide platform (WeGuide is a patient engagement software platform that allows for enrolment, consent, and data collection \\[via questionnaires\u002Fsurveys and from the Garmin Smartwatches\\] through a singular platform).",[61,62,63,26,64,65,66],"Urinary Tract Infection","Cellulitis","Impetigo","Tonsillitis","Respiratory Tract Infections","Otitis Media",[68,69,70,71],"Paediatrics","Antibiotics","Digital Health","Infection","2025-09-17",{"date":74,"type":37},"2025-09-22",{"date":76,"type":37},"2025-09-16",{"date":78,"type":20},"2026-08",{"name":80,"class":81},"Murdoch Childrens Research Institute","OTHER",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100580877","phase-2-study-to-evaluate-the-efficacy-and-safety-of-different-doses-of-graminidin-with-anesthetic-a-metered-dose-topical-spray-in-the-treatment-of-acute-infectious-and-inflammatory-pharyngeal-diseases-compared-with-drug-septolete-total-lozenges-100580877","NCT06843018","Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges","A Prospective, Open-label, Multicenter, Comparative, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Different Doses of the Drug Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges","Inclusion Criteria:\n\n1. Male or female patients aged 18 to 75 years inclusive.\n2. Symptom \"sore throat\" due to infectious-inflammatory diseases of the pharynx (acute pharyngitis, acute nasopharyngitis, exacerbation of chronic pharyngitis) based on one or more of the following clinical manifestations:\n\n   * Unpleasant sensations\u002Fdiscomfort in the throat - symptoms of pharyngeal paresthesia (scratchy throat, dryness or sore sensation (\"foreign body\" sensation));\n   * Painful sensations in the throat, including sore throat at rest, throat burning, or pain upon swallowing saliva;\n3. Severity of the symptom \"sore throat\" from 55 mm to 80 mm on the Visual Analog Scale (VAS).\n4. A score of 5 to 8 points on the Clinical Symptom Severity Scale for tonsillopharyngitis.\n5. Absence of indications for systemic antibacterial therapy at the time of inclusion in the study.\n6. Negative test result for β-hemolytic streptococcus.\n7. Duration of disease symptoms not exceeding 3 days at the time of inclusion in the study.\n8. Women with a negative pregnancy test who have used one or more of the following contraceptive methods for 8 weeks prior to and during the 3 weeks after the end of the study: intrauterine devices (IUDs), oral contraceptives, contraceptive patches, long-acting injectable contraceptives, double barrier contraceptive method; or women who are infertile (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year); or men using a double barrier contraceptive method (condom with spermicide) throughout the study and for 3 weeks after its conclusion or men who are infertile (documented conditions: vasectomy, infertility).\n9. Signed and dated informed consent form.\n\nNon-inclusion Criteria:\n\n1. Trauma and\u002For burns of the oropharynx, scarlet fever, rubella, measles at the time of inclusion in the study and not earlier than 3 months before inclusion in the study.\n2. Treatment with any systemic antibacterial agents within 14 days prior to inclusion in the study.\n3. Use of non-steroidal anti-inflammatory drugs and\u002For decongestants within 12 hours prior to the randomization visit.\n4. Body temperature at screening and randomization visits ≥ 38.5 °C.\n5. Infectious-inflammatory diseases requiring combined or systemic antibacterial therapy.\n6. Severe, decompensated, or unstable somatic diseases (any diseases or conditions that threaten the patient's life or worsen the prognosis of the underlying disease, as well as make it impossible for the patient to participate in the clinical study).\n7. History of malignancy, exept for subjects who have been disease-free for at least 5 years prior to screening.\n8. Allergic history.\n9. Participation in any other clinical study within 90 days prior to inclusion in the study.\n10. Pregnancy or breastfeeding in women.\n11. Refusal to use effective contraceptive methods during the study.\n12. Alcoholism, drug addiction, abuse of psychotropic medications, including in history.\n13. Smoking more than 10 cigarettes per day.\n14. Positive urine test for narcotic substances and potent medications.\n15. Vaccination within 21 days prior to study enrollment.\n16. Other conditions that, in the opinion of the investigator, prevent the patient from being included in the study.\n\nExclusion Criteria:\n\n1. Erroneous inclusion of a patient in the study (not meeting inclusion\u002Fexclusion criteria at the time of randomization).\n2. Ineffectiveness of therapy. Therapy will be considered ineffective if there is no clinical improvement by Visit 2 (Day 3-4 of therapy) - persistence or worsening of the symptom \"sore throat\" and catarrhal phenomena compared to baseline data. If excluded, the patient will be assigned alternative treatment at the discretion of the investigator.\n3. Patient non-compliance (a patient is considered compliant if the number of applications of the study drug\u002Fcomparison drug is not less than 17 and not more than 25).\n4. Smoking more than 10 cigarettes per day.\n5. Requirement for prohibited concomitant therapy.\n6. The investigator determines that continued participation in the study may pose a risk to the subject's safety or well-being.\n7. Pregnancy or breastfeeding.\n8. Gross violation by the patient of the study protocol procedures presented in the patient information sheet (PIS).\n9. Withdrawal of informed consent (the patient's unwillingness to continue participation in the study).\n10. Loss of contact with the patient (inability to reach the patient by mobile and home phone (if applicable), as well as through a contact person; there must be at least three documented attempts to contact the patient).\n11. The emergence during the study of any diseases or conditions that worsen the patient's prognosis and make it impossible for the patient to continue participating in this clinical study.\n12. Any other reasons, including administrative ones, that in the investigator's judgment would prevent the subject from completing the study.","18 Years","75 Years",{"count":57,"type":20},[94],"PHASE2","This study aims to evaluete of tthe efficacy and safety of using different doses of the drug Grammidin with anesthetic, a metered dose topical spray, in the treatment of acute infectious and inflammatory pharyngeal diseases.",[97,26,98,99],"Pharyngitis Acute","Nasopharyngitis","Exacerbation of Chronic Pharyngitis","2025-07-04",{"date":102,"type":37},"2025-07-10",{"date":104,"type":37},"2024-11-14",{"date":106,"type":20},"2026-12-31",{"name":108,"class":109},"Valenta Pharm JSC","INDUSTRY",12,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":16,"minAge":90,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":82},"100582128","phase-1-safety-tolerability-and-pharmacokinetic-profile-of-grammidin-a-metered-dose-topical-spray-in-healthy-volunteers-100582128","NCT06859281","Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers","An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of the Drug Grammidin, a Metered Dose Topical Spray Following Single Administration in Healthy Volunteers","Inclusion Criteria:\n\n1. Voluntarily and personally signed informed consent form by a healthy volunteer obtained prior to the conduct of any study-related procedure;\n2. Males and females aged 18 to 45 years (inclusive);\n3. Verified healthy status as demonstrated by the absence of clinically significant abnormalities in medical history, physical examination, laboratory tests, and other diagnostic procedures specified in the protocol;\n4. Blood pressure (BP) level: systolic blood pressure (SBP) from 99 to 129 mm Hg (inclusive), diastolic blood pressure (DBP) from 70 to 89 mm Hg (inclusive);\n5. Heart rate (HR) from 60 to 89 beats per minute (inclusive);\n6. Respiratory rate (RR) from 12 to 20 breaths per minute (inclusive);\n7. Body temperature from 36.0°C to 36.9°C (inclusive);\n8. Body mass index (BMI) between 18.5 kg\u002Fm² and 30 kg\u002Fm², with a minimum body weight of ≥ 55 kg for men and ≥ 45 kg for women;\n9. Consent to use adequate contraceptive methods throughout the study and for 30 days after its completion, with a negative urine pregnancy test result for women of childbearing potential.\n\nNon-Inclusion Criteria:\n\n1. Clinically significant allergic history;\n2. Hypersensitivity to active and\u002For excipient substances in the investigational drug and comparator drug in the medical history;\n3. Drug intolerance to active and\u002For excipient substances in the investigational drug and comparator drug in the medical history;\n4. Chronic diseases of the kidneys, liver, gastrointestinal tract (GIT), cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, urogenital, and immune systems, as well as skin, hematopoietic organs, and the eye;\n5. Erosive-ulcerative lesions of the oral mucosa (aphthous stomatitis, mechanical trauma due to dental diseases, herpes lesions, and any other condition resulting in compromised integrity of the oral mucosa);\n6. Surgical interventions on the GIT in the medical history (except for appendectomy performed at least 1 year prior to screening);\n7. Diseases\u002Fconditions that, in the investigator's judgment, may affect the absorption, distribution, metabolism, or excretion of the investigational drugs;\n8. Acute infectious diseases less than 4 weeks before screening;\n9. Use of medications (drugs) that significantly affect hemodynamics and drugs affecting liver function (barbiturates, omeprazole, cimetidine, etc.) less than 2 months before screening;\n10. Regular use of medications less than 2 weeks before screening and single use of medications less than 7 days before screening (including over-the-counter medications, vitamins, dietary supplements, herbal medicines);\n11. Blood or plasma donating within 3 months prior to screening;\n12. Use of hormonal contraceptives (in women) within 2 months prior to screening;\n13. Use of depot injections of any medications within 3 months prior to screening;\n14. Pregnancy or lactation; positive urine pregnancy test result for women of childbearing potential;\n15. Female subjects of childbearing potential who had unprotected sexual intercourse with an unsterilized male partner within 30 days prior to administration investigational drugs;\n16. Participation in another clinical study within 3 months prior to screening or concurrently with this study;\n17. Consumption of more than 10 alcohol units per week (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of wine, or 50 ml of strong alcoholic beverages) in the last month before inclusion in the study or a history of alcoholism, drug addiction, or substance abuse;\n18. Smoking more than 10 cigarettes per day currently or smoking that amount in the past 6 months prior to screening; unwillingness to refrain from smoking during hospitalization;\n19. Consumption of alcohol, caffeine, and xanthine-containing products within 7 days prior to taking investigational drugs;\n20. Consumption of citrus fruits, cranberries, rose hips and products containing them, or preparations\u002Fproducts containing St. John's wort within 7 days prior to taking investigational drugs;\n21. Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours prior to taking investigational drugs;\n22. Positive blood test for antibodies to human immunodeficiency virus (HIV) types 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens during screening;\n23. Positive rapid test for SARS-CoV-2 at screening;\n24. ECG abnormalities in medical history and\u002For during screening;\n25. Positive urine test for narcotic substances and potent medications during screening;\n26. Positive breath alcohol test result during screening;\n27. Planning hospitalization during the study period for any reason other than hospitalization specified in this protocol;\n28. Inability or unwillingness to comply with protocol requirements, perform procedures prescribed by the protocol, or adhere to dietary and activity restrictions;\n29. Membership in a vulnerable population? including but not limited to students of medical, pharmaceutical and dental educational institutions, junior staff of clinics and laboratories, employees of pharmaceutical companies, military personnel, prisoners, residents of care facillities, individuals with low income or unemployed, members of ethnic minorities, homeless persons, vagrants, refugees, individuals under guardianship or conservatorship, ndividuals unable to provide informed consent and law enforcement personnel;\n30. Dental procedures performed within 3 weeks prior to screening;\n31. Other conditions that in the judgment of the Investigator may prevent volunteer inclusion in the study or lead to premature withdrawal from the study including adherence to fasting or special diets (e.g., vegetarianism, veganism, salt restriction) or special lifestyles (night work, extreme physical exertion).\n\nExclusion Criteria:\n\n1. Withdrawal of the volunteer from further participation in the study;\n2. Non-compliance by the volunteer with the study participation rules (missed study procedures, self-administration of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.);\n3. Emergence of reasons\u002Fsituations during the study that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.);\n4. Volunteers selected for participation in the study who do not meet inclusion\u002Fexclusion criteria;\n5. Development of a severe adverse event (SAE) in the volunteer during the study;\n6. The volunteer undergoes or requires treatment that may affect the pharmacokinetic parameters (PKP) of the investigational drugs;\n7. Missed collection of 2 or more consecutive blood samples or 3 or more blood samples within one study period;\n8. Occurrence of vomiting\u002Fdiarrhea within 6 hours after taking the investigational drug;\n9. Positive urine test for narcotic substances and potent medications;\n10. Positive breath test for alcohol vapors;\n11. Positive pregnancy test result in women;\n12. Positive SARS-CoV-2 test result;\n13. Emergence of other reasons during the study that prevent conducting the study according to the protocol.",true,"45 Years",{"count":121,"type":20},24,[123],"PHASE1","This study aims to evaluate the safety, tolerability, and pharmacokinetic profile of the Grammidin, a metered dose topical spray, compared to Grammidin lozenges following single administration in healthy volunteers .",[26],{"date":102,"type":37},{"date":128,"type":37},"2024-12-10",{"date":130,"type":20},"2026-12-01",{"name":108,"class":109},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":16,"minAge":90,"maxAge":119,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":82},"100582021","phase-1-safety-tolerability-and-pharmacokinetic-profile-of-grammidin-with-anesthetic-a-metered-dose-topical-spray-in-healthy-volunteers-100582021","NCT06857890","Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers","An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of the Drug Grammidin With Anesthetic, a Metered Dose Topical Spray Following Single Administration in Healthy Volunteers",{"count":121,"type":20},[123],"This study aims to evaluate the safety, tolerability, and pharmacokinetic profile of the Grammidin with anesthetic, a metered dose topical spray, compared to Grammidin with anesthetic neo, lozenges following single administration in healthy volunteers.",[26],{"date":102,"type":37},{"date":144,"type":37},"2024-12-09",{"date":130,"type":20},{"name":108,"class":109},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":159,"studyType":160,"phases":4,"briefSummary":161,"conditions":162,"keywords":169,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":82},"100398696","pediatric-and-ambulatory-research-in-infectious-diseases-100398696","NCT04471493","Pediatric and Ambulatory Research in Infectious Diseases","Real Time Surveillance of Pediatric Infectious Diseases in French Ambulatory Care: PARI Study","PARI","Inclusion Criteria:\n\n* Children under 16 years of age with at least one infectious disease among:\n* pharyngitis\n* otitis\n* pneumonia\n* influenza\n* bronchiolitisz\n* varicella\n* gastroenteritis\n* enterovirus disease\n* bordetella pertussis disease\n* using the same same software, Axi5-Infansoft (developed by CompuGroup Medical, Nanterre, France)\n\nExclusion Criteria:\n\n* parental refusal","1 Day","16 Years",{"count":158,"type":20},400000,"5 Years","OBSERVATIONAL","Many ambulatory networks are mainly based on diagnoses made by first-line physicians not specifically trained to join the network. Here we aim to set up a surveillance network on pediatric infectious diseases with an investment in teaching with specific trainings of participating pediatricians, increasing in use of point of care tests, and automated data extraction from the computers of the pediatricians.",[163,164,165,26,166,167,168],"Otitis","Bronchiolitis","Influenza","Varicella","Pneumonia","Gastroenteritis",[170,171,172,173,174],"Vaccination","Antibiotic treatment","Point of care test","automated data extraction","network","2024-02-07",{"date":177,"type":37},"2024-02-08",{"date":179,"type":37},"2017-06-26",{"date":181,"type":20},"2030-08-02",{"name":183,"class":81},"Association Clinique Thérapeutique Infantile du val de Marne"]